Organization | Medizinische Hochschule Hannover

Medizinische Hochschule Hannover Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2018

NCT03572582

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Alternative names

Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel | Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie & Endokrinologie

Active Ingredients

Drugs in Phase 2 Trials (7)

chlorotrianisene (tace) (1 trial)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (1 trial)

lenvatinib (lenvima) (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (2 trials)

trastuzumab (herceptin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Liver Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 7